Calidi Biotherapeutics
CLDI
27 hedge funds and large institutions have $165M invested in Calidi Biotherapeutics in 2021 Q4 according to their latest regulatory filings, with 27 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.61% more ownership
Funds ownership: 0% → 0.61% (+0.61%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AMH
Apollo Management Holdings
New York
|
+$19.4M |
| 2 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$19.4M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$19.4M |
| 4 |
HCM
Highbridge Capital Management
New York
|
+$15.6M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$14.7M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| $73K | +$73.1K | +62 | New |
|
|
DFCM
27
Dark Forest Capital Management
San Juan,
Puerto Rico
| $13K | +$13K | +11 | New |
|
CLDI Hedge Fund Activity: Q4 2021 in Review
27 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q4 2021, worth a combined $165M.
Buyers outnumbered sellers: 27 funds opened new CLDI positions and 0 closed out — a net gain of 27 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Apollo Management Holdings, opening a new position worth an estimated $19.4M.
- 27 institutional investors held Calidi Biotherapeutics (CLDI) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $165M of Calidi Biotherapeutics stock for Q4 2021.
- 27 funds opened new Calidi Biotherapeutics positions in Q4 2021 and 0 closed out, a net change of +27 holders.
- The largest Calidi Biotherapeutics buyer in Q4 2021 was Apollo Management Holdings, an estimated $19.4M added.
Based on aggregated 13F filings for Q4 2021.